Lyell Immunopharma Inc (LYEL)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current LYEL market cap is 144.38M. The company's latest EPS is USD -23.1626 and P/E is -0.42.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.09M | 989k | 764k | 524k | 126k |
| Operating Income | -55.58M | -51.53M | -50.51M | -149.85M | -57.37M |
| Net Income | -60.67M | -45.81M | -44.58M | -191.94M | -52.2M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 17.19M | 12.97M | 89.44M | 2.92M | 3.37M |
| Operating Income | -211.94M | -214.78M | -187.06M | -247.01M | -307.46M |
| Net Income | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 694.22M | 654.14M | 619.22M | 490.86M | 429.8M |
| Total Liabilities | 91.06M | 87.64M | 88.52M | 108.04M | 93.28M |
| Total Equity | 603.16M | 566.5M | 530.7M | 382.82M | 336.52M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 908.28M | 1.13B | 937.56M | 750.03M | 490.86M |
| Total Liabilities | 189.84M | 197.62M | 104.31M | 95.08M | 108.04M |
| Total Equity | -292.53M | 929.79M | 833.25M | 654.95M | 382.82M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -42.02M | -80.11M | -115.15M | -162.39M | -54.74M |
| Investing | 21.99M | 67M | 68.92M | 122.42M | 69.47M |
| Financing | 27k | 889k | 889k | 1.33M | 1,000 |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -160.87M | -126.25M | -169.56M | -163.69M | -162.39M |
| Investing | -273.52M | -121.57M | -11.54M | 184.05M | 122.42M |
| Financing | 476.79M | 401.24M | 10.64M | 1.74M | 1.33M |
| Market Cap | 144.38M |
| Price to Earnings Ratio | -0.42 |
| Price to Sales Ratio | 42.88 |
| Price to Cash Ratio | 1.37 |
| Price to Book Ratio | 0.38 |
| Dividend Yield | - |
| Shares Outstanding | 14.81M |
| Average Volume (1 week) | 56k |
| Average Volume (1 Month) | 155.98k |
| 52 Week Change | -70.81% |
| 52 Week High | 38.40 |
| 52 Week Low | 7.65 |
| Spread (Intraday) | 0.77 (7.55%) |
| Company Name | Lyell Immunopharma Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://lyell.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
